Dickson, M. A., Schwartz, G. K., Keohan, M. L., D’Angelo, S. P., Gounder, M. M., Chi, P., . . . Tap, W. D. (2016). Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma. JAMA Oncol.
Style de citation ChicagoDickson, Mark A., et al. "Phase 2 Trial of the CDK4 Inhibitor Palbociclib (PD0332991) At 125 Mg Dose in Well-Differentiated or Dedifferentiated Liposarcoma." JAMA Oncol 2016.
Style de citation MLADickson, Mark A., et al. "Phase 2 Trial of the CDK4 Inhibitor Palbociclib (PD0332991) At 125 Mg Dose in Well-Differentiated or Dedifferentiated Liposarcoma." JAMA Oncol 2016.
Attention : ces citations peuvent ne pas être correctes à 100%.